At this market cap, to have a drug that has been objectively assessed via biomarkers (albeit not statistically significant yet) to be a disease modifying drug for a neurological disorder with no current treatment is as good as it gets imo. The 201 readout next year is going to be a watershed moment for MSA sufferers I think.
This can be a US500 M net annual sales drug within 5 years if the science continues to play out....
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-74
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $648.3K | 128.1M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4901441 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 22097257 | 20 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |